Form 8-K - Current report:
SEC Accession No. 0001213900-25-074983
Filing Date
2025-08-12
Accepted
2025-08-12 16:21:39
Documents
17
Period of Report
2025-08-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0252890-8k_immucell.htm   iXBRL 8-K 29198
2 LOAN AGREEMENT BETWEEN THE COMPANY AND MAINE COMMUNITY BANK DATED AS OF AUGUST 7 ea025289001ex10-1_immucell.htm EX-10.1 191944
3 PROMISSORY NOTE EXECUTED BY THE COMPANY IN FAVOR OF MAINE COMMUNITY BANK DATED A ea025289001ex10-2_immucell.htm EX-10.2 38007
4 PRESS RELEASE OF THE COMPANY DATED AUGUST 12, 2025 ea025289001ex99-1_immucell.htm EX-99.1 14925
5 GRAPHIC ex10-1_001.jpg GRAPHIC 24227
6 GRAPHIC ex10-2_001.jpg GRAPHIC 23705
  Complete submission text file 0001213900-25-074983.txt   569400

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE iccc-20250807.xsd EX-101.SCH 3014
8 XBRL LABEL FILE iccc-20250807_lab.xml EX-101.LAB 34239
9 XBRL PRESENTATION FILE iccc-20250807_pre.xml EX-101.PRE 22358
19 EXTRACTED XBRL INSTANCE DOCUMENT ea0252890-8k_immucell_htm.xml XML 3558
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 251207050
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)